Success Metrics

Clinical Success Rate
100.0%

Based on 21 completed trials

Completion Rate
100%(21/21)
Active Trials
4(15%)
Results Posted
24%(5 trials)

Phase Distribution

Ph phase_3
5
19%
Ph phase_4
1
4%
Ph phase_2
3
11%
Ph early_phase_1
2
7%
Ph phase_1
1
4%
Ph not_applicable
14
52%

Phase Distribution

3

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution26 total trials
Early Phase 1First-in-human
2(7.7%)
Phase 1Safety & dosage
1(3.8%)
Phase 2Efficacy & side effects
3(11.5%)
Phase 3Large-scale testing
5(19.2%)
Phase 4Post-market surveillance
1(3.8%)
N/ANon-phased studies
14(53.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.5%

21 of 22 finished

Non-Completion Rate

4.5%

1 ended early

Currently Active

4

trials recruiting

Total Trials

27

all time

Status Distribution
Active(4)
Completed(21)
Terminated(1)
Other(1)

Detailed Status

Completed21
Recruiting3
Active, not recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (7.7%)
Phase 11 (3.8%)
Phase 23 (11.5%)
Phase 35 (19.2%)
Phase 41 (3.8%)
N/A14 (53.8%)

Trials by Status

active_not_recruiting14%
completed2178%
recruiting311%
unknown14%
withdrawn14%

Recent Activity

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT06494488Early Phase 1

Differential Thrombogenesis by EPA and DHA Mediated by HDL

Recruiting
NCT06207071Not Applicable

Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial

Recruiting
NCT02647723Not Applicable

Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation

Active Not Recruiting
NCT03613844Phase 2

DHA Brain Delivery Trial

Completed
NCT00646360Not Applicable

Effects of Prenatal DHA Supplements on Infant Development

Completed
NCT02517502Early Phase 1

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

Completed
NCT04972643Not Applicable

The Protective Effect of Omega-3 Fatty Acid on Cognitive Function Among Patients With Mild Dementia

Completed
NCT02670382Not Applicable

Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids

Completed
NCT04746885Not Applicable

Effect of DHA on Proinflammatory Cytokines Including Platelets Activating Factor (PAF) in Preterm Neonates

Completed
NCT04249635

Fetal Programming of Immune Response and Body Fat by Maternal Obesity

Completed
NCT03014115Not Applicable

Effects of Different ARA Formulations of Infant Formula on Fatty Acid Status, Immune Markers and Infection Rates in Infants

Completed
NCT03965988Phase 3

Docosahexaenoic Acid on Breath Holding Spells in Children

Recruiting
NCT03109626Not Applicable

Docosahexaenoic Acid (DHA) Replacement for Treatment in Spinocerebellar Ataxia 38

Completed
NCT03569501Not Applicable

Impact of DHA/Oat on Metabolic Health in Gestational Diabetes Mellitus

Unknown
NCT02487771Phase 3

Kansas University DHA Outcome Study (KUDOS) Follow-Up

Completed
NCT02889341Not Applicable

Valuation of Variable Dose of Docosahexanoic Acid for the Improvement of the Parameters of Male Fertility

Completed
NCT01936194Not Applicable

The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis

Withdrawn
NCT00266825Phase 3

DHA Supplementation and Pregnancy Outcome

Completed
NCT01940640Phase 2

Effect of Mother DHA Supplementation on Premature Newborn.

Completed
NCT02615405Not Applicable

Phospholipid Hypothesis of Depression: From Molecular Biology, Neuroimaging to Behaviour

Completed

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
27